Co-Diagnostics reports FY2021 revenue $97.9M, EPS $1.23; guides Q1 FY2022 revenue $21-22M

Co-Diagnostics, Inc.

Revenue $97.9M, +$23.3M YoY; net income $36.7M ($1.23 diluted EPS) vs $42.5M ($1.52) in 2020.
Adjusted EBITDA $52.1M, up from $45.3M in 2020; cash & securities $89.9M at Dec 31, 2021.
Q1 FY2022 guidance: revenue $21-22M, diluted EPS $0.17-0.20, shares 32.4M.
Gross profit $86.3M (88.2% margin); operating income $46.1M on record revenue.
2021 highlights: at-home PCR platform, acquisitions of Idaho Molecular & Advanced Conceptions, CDSCO clearance for ABC test in India.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.